Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
Srdan Verstovsek, Constantine S Tam, Martha Wadleigh, Lubomir Sokol, Catherine C Smith, Lynne A Bui, Chunyan Song, Douglas O Clary, Patrycja Olszynski, Jorge Cortes, Hagop Kantarjian, Neil P Shah
Leukemia Research | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2014
Awarded by MD Anderson Cancer Center Support Grant
This work was supported by funding from the Leukemia & Lymphoma Society (to CCS and NPS), the UCSF T-32 Molecular Mechanisms of Cancer grant (to CCS), the MD Anderson Cancer Center Support Grant CA016672, and Art and Alison Kern.